Is there a correlation between molecular markers and response to neoadjuvant chemoradiotherapy in locally advanced squamous cell esophageal cancer?

Journal of B.U.ON.

Volumn 17, Issue 4, 2012, Pages 706-711

  Arsenijevic, Tatjana ^a,b   Micev, M ^b,c   Nikolic, V ^a   Gavrilovic, D ^a   Radulovic, S ^a   Pesko, P ^b,c  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Chemoradiation; Esophageal cancer; Molecular markers

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; PROTEIN P21; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE SEVERITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872407832     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systemic review and meta-analysis. GUT 2004; 53: 925-930. (Pubitemid 38824146)
2. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317. (Pubitemid 46218723)
3. Berger B, Belka C. Evidence-based radiation oncology: Oesophagus. Radiother Oncol 2009; 92: 276-290.
4. Urba S. Esophageal cancer: preoperative or definitive chemoradiation. Ann Oncol 2004; 15: iv93-iv96. (Pubitemid 39585318)
5. Geh JI, Bond SJ, Bentzen SM et al. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006; 78: 236-244.
6. Kaklamanos I, Walker GR, Ferry K et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta analysis of randomized clinical trials. Ann Surg Oncol 2003; 11: 754-761. (Pubitemid 40486875)
7. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174. (Pubitemid 34177421)
8. Crehange G, Maingon P, Peignaux K et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. J Clin Oncol 2007; 25: 4895-4901. (Pubitemid 350220419)
9. Imdahl A, Bognar G, Schulte-Mönting J, Schöffel U, Farthrnann EH, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothor Surg 2002; 21: 657-663. (Pubitemid 34257953)
10. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 1994; 73: 2680-2686. (Pubitemid 24166250)
11. Vallböhmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006; 19: 425-432.
12. Berger AC, Farma J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337. (Pubitemid 46207006)
13. Gibault L, Metges JP, Conan-Charlet V et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005; 93: 197-115.
14. Ozawa S, Ueda M, Ando N, Shimizu N, Abe O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 1989; 63: 2169-2173. (Pubitemid 19136849)
15. Akamatsu M, Matsumoto T, Oka K et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003; 57: 1323-1327. (Pubitemid 37443972)
16. Delektorskaya W, Chemeris GY, Kononets PV et al. Clinical significance of hyperexpression of epidermal growth factor receptors (EGFR and HER-2) in esophageal squamous cell carcinoma. Oncology 2009; 148: 241-245.
17. Ikeda K, Ishida K, Sato N et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus 2001; 14: 197-201. (Pubitemid 34170808)
18. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092.
19. Izbicki JR, Hosch SB, Pichlmeier U et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997; 337: 1188-1194. (Pubitemid 27454450)
20. Fareed KR, Kaye P, Soomro IN et al. Biomarkers of response to therapy in oesophago-gastric cancer. GUT 2009; 58: 127-143.
21. National Cancer Institute, Division of Cancer Treatment, NCI-Common Toxicity Criteria, Version 2.0, 1999.
22. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
23. Ku GY, Ilson HD. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010; 36: 235-248.
24. Han U, Can OI, Kayhan B, Onal BU. Expression of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastases of esophageal squamous cell carcinoma? Dis Esophagus 2007; 20: 379-385. (Pubitemid 47323676)
25. Okumura H, Natsugoe S, Matsumoto M et al. The predictive value of p53, p53R2 and p21 for the effect of chemoradiotherapy in esophageal squamous cell carcinoma. Br J Cancer 2005; 92: 284-289. (Pubitemid 40343142)